3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Neuroendocrine Tumors
394
Multiple Endocrine Neoplasia Type 1
156
Carcinoma, Neuroendocrine
123
Thyroid Cancer, Papillary
118
Pituitary Neoplasms
116
Thyroid Neoplasms
100
Pheochromocytoma
91
Neoplasms
79
Carcinoid Tumor
76
Thyroid Carcinoma, Anaplastic
73
Adrenocortical Carcinoma
73
Paraganglioma
65
Neoplasm Metastasis
56
Adenocarcinoma, Follicular
53
Carcinoma, Non-Small-Cell Lung
51
Carcinoma, Medullary
50
Insulinoma
49
Pancreatic Neoplasms
47
Adenoma, Islet Cell
47
Colorectal Neoplasms
44
Breast Neoplasms
44
Small Cell Lung Carcinoma
42
Sarcoma
42
Gastro-enteropancreatic neuroendocrine tumor
42
Carcinoma, Renal Cell
41
Somatostatinoma
38
Head and Neck Neoplasms
38
Melanoma
37
Lung Neoplasms
37
Adrenal Gland Neoplasms
34
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
Endocrine
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled